Barr实验室第四季度的收入突出部分居首位
NEW YORK (Reuters Health) - Despite a slowdown in sales of its generic breast cancer drug tamoxifen, Barr Laboratories said on Wednesday that its fiscal fourth quarter earnings per share should arrive between $0.49 and $0.51, topping the current First Call/Thomson Financial consensus estimate of $0.43 per share.
The earnings will beat projections for a number of reasons, including unexpectedly high sales of products other than tamoxifen and a strong mix of sales from higher-margin products, the company said.
"These more than offset lower than expected sales of tamoxifen," Barr said.
Full fiscal fourth quarter financial results are slated to be released on August 7.
On Tuesday, shares of Pomona, New York-based Barr closed on the New York Stock Exchange at 64.70, off a 52-week high of 80.125., 百拇医药
The earnings will beat projections for a number of reasons, including unexpectedly high sales of products other than tamoxifen and a strong mix of sales from higher-margin products, the company said.
"These more than offset lower than expected sales of tamoxifen," Barr said.
Full fiscal fourth quarter financial results are slated to be released on August 7.
On Tuesday, shares of Pomona, New York-based Barr closed on the New York Stock Exchange at 64.70, off a 52-week high of 80.125., 百拇医药